[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623654":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":127,"collaborators":129,"id":133,"slug":19,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":134,"sex":140,"minAge":141,"maxAge":19,"enrollmentInfo":142,"targetDuration":19,"studyType":145,"phases":146,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":153,"whyStopped":19,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LVIVO-TaVec400 product","EXPERIMENTAL","Each subject will be given a single-dose LVIVO-TaVec400 product infusion at each dose level",[13],"Biological: LVIVO-TaVec400 product",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Prior to infusion of the LVIVO-TaVec400 product, subjects will receive bridging therapy if needed.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Lugui Qiu","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Gang An","CONTACT","+86 022-23909083","angang@ihcams.ac.cn",{"name":31,"role":27,"phone":19,"phoneExt":19,"email":32},"Jianling Yao","jianling.yao@legendbiotech.cn",[34,54,69,84,100,115],{"facility":35,"status":19,"city":36,"state":37,"zip":19,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Henan Cancer Hospital","Zhengzhou","Henan","China",{"type":40,"coordinates":41},"Point",[42,43],113.64861,34.75778,{"lat":43,"lon":42},[46,50,52],{"name":47,"role":27,"phone":48,"phoneExt":19,"email":49},"Baijun Fang","+86 0371-65587318","fdation@126.com",{"name":51,"role":23,"phone":19,"phoneExt":19,"email":19},"Baijun Fang, Doctor",{"name":53,"role":23,"phone":19,"phoneExt":19,"email":19},"Quande Lin, Doctor",{"facility":55,"status":19,"city":56,"state":57,"zip":19,"country":38,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei",{"type":40,"coordinates":59},[60,61],114.26667,30.58333,{"lat":61,"lon":60},[64,68],{"name":65,"role":27,"phone":66,"phoneExt":19,"email":67},"Chunrui Li, Doctor","+86 027-83662640","cunrui5650@126.com",{"name":65,"role":23,"phone":19,"phoneExt":19,"email":19},{"facility":70,"status":19,"city":71,"state":72,"zip":19,"country":38,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"The Affiliated Hospital of Xuzhou Medical University","Xuzhou","Jiangsu",{"type":40,"coordinates":74},[75,76],117.28386,34.20442,{"lat":76,"lon":75},[79,83],{"name":80,"role":27,"phone":81,"phoneExt":19,"email":82},"Zhiling Yan, Doctor","+86 0516-85806985","Hematology_md@126.com",{"name":80,"role":23,"phone":19,"phoneExt":19,"email":19},{"facility":85,"status":19,"city":86,"state":87,"zip":19,"country":38,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"The First Affiliated Hospital of Nanchang University","Nanchang","Jiangxi",{"type":40,"coordinates":89},[90,91],115.85306,28.68396,{"lat":91,"lon":90},[94,98],{"name":95,"role":27,"phone":96,"phoneExt":19,"email":97},"Fei Li","+86 0791-88693146","ncyf.lifei@outlook.com",{"name":99,"role":23,"phone":19,"phoneExt":19,"email":19},"Fei Li, Doctor",{"facility":101,"status":19,"city":102,"state":19,"zip":19,"country":38,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Beijing GoBroad Boren Hospital","Beijing",{"type":40,"coordinates":104},[105,106],116.39723,39.9075,{"lat":106,"lon":105},[109,113],{"name":110,"role":27,"phone":111,"phoneExt":19,"email":112},"Yajing Zhang","+86 010-63290505","23975701@qq.com",{"name":114,"role":23,"phone":19,"phoneExt":19,"email":19},"Yajing Zhang, Doctor",{"facility":116,"status":19,"city":117,"state":19,"zip":19,"country":38,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Institute of Hematology & Blood Diseases Hospital","Tianjin",{"type":40,"coordinates":119},[120,121],117.17667,39.14222,{"lat":121,"lon":120},[124,126],{"name":125,"role":27,"phone":28,"phoneExt":19,"email":29},"Gang An, Doctor",{"name":125,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":128,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[130],{"name":131,"class":132},"Nanjing Legend Biotech Co.","INDUSTRY","100623654",false,"NCT07399444","A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed\u002FRefractory Multiple Myeloma（LB2505-0001）","A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the LVIVO-TaVec400 Product in the Treatment of Relapsed\u002FRefractory Multiple Myeloma","LB2505-0001","Inclusion Criteria:\n\n1. Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up.\n2. Age ≥ 18 years.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Has measurable lesions\n5. Relapsed and\u002For refractory multiple myeloma\n6. Life expectancy≥ 3 months\n7. Clinical laboratory values meet screening visit criteria\n8. Adequate organ function.\n\nExclusion Criteria:\n\n1. Prior antitumor therapy with insufficient washout period ;\n2. Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab).\n3. Those who have experienced life-threatening allergic reactions, hypersensitivity reactions or intolerances to the excipients and related additives of the investigational drug; or those with a previous history of severe allergic reactions (such as hypersensitivity reactions, or those for whom the investigator assesses the need to use glucocorticoids to prevent severe immune-related reactions such as allergic reactions).\n4. Any condition deemed by the investigator as rendering the subject unsuitable for participation in this study.\n5. Also enrolled in other clinical studies.","ALL","18 Years",{"count":143,"type":144},38,"ESTIMATED","INTERVENTIONAL",[147],"EARLY_PHASE1","This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed\u002Frefractory multiple myeloma.",[150],"Multiple Myeloma (MM)",[152],"Relapsed\u002FRefractory multiple myeloma","NOT_YET_RECRUITING","2026-02-02",{"date":156,"type":157},"2026-02-10","ACTUAL",{"date":159,"type":144},"2026-01-10",{"date":161,"type":144},"2030-05-10",{"name":5,"class":6},6]